KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.90

Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study.

Ga Won Yim, Kyung Hee Han, Soon Tae Lee, Maria Lee, Seung Mee Lee, Hee Seung Kim

BMC Med 24(1) 131

PMID41630017
PMCIDPMC12951986
DOI10.1186/s12916-026-04637-x
发表日期2026-02-03
入排依据:The study is a randomized Phase III trial in human ovarian cancer with a drug intervention, but the primary endpoint is a binary toxicity outcome (CIPN incidence), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). While survival is mentioned as a secondary endpoint, it is not the primary or key secondary focus, and no Kaplan-Meier or HR results are provided for a time-to-event efficacy outcome.
摘要

摘要

BACKGROUND: Chemotherapeutic agents for ovarian cancer commonly cause chemotherapy-induced peripheral neuropathy (CIPN), significantly impairing quality of life (QoL). Selenium, a potent antioxidant, may mitigate toxicity and improve QoL in cancer patients. This study evaluated intravenous high-dose selenium for preventing neuropathic symptoms in platinum-sensitive recurrent ovarian cancer (PSROC). METHODS: A phase 3, double-blind, parallel group, randomized controlled pilot trial enrolled 68 patients with PSROC, randomized 1:1 to the experimental (selenium) and control (placebo) groups. Patients received sodium selenite pentahydrate (2000 µg /40 mL) or normal saline intravenously two hours before paclitaxel-carboplatin-bevacizumab infusion for six cycles. The primary endpoint was the incidence of grade 1 or more CIPN at 3 months following six cycles of chemotherapy, comparing the experimental group to the control group. Secondary endpoints included comparisons of grade 1 or more, grade 2 or more CIPN before each cycle, 3 weeks and 3 months after six cycles of chemotherapy, adverse events, QoL, and the need for concomitant medications to manage CIPN, and survival between the two groups. RESULTS: We enrolled sixty-eight patients in the study. The incidence of grade 1 or more CIPN did not differ between the two groups at 3 months post-chemotherapy. However, grade 2 or motor dysfunction incidence was significantly lower in the experimental group before cycle 3 (3.3% vs. 23.3%; P = 0.02) and before cycle 4 (3.3% vs. 20%; P = 0.04), particularly in patients ≥ 60 years. QoL showed no statistically significant difference between the two groups. Duloxetine/gabapentin usage and adverse events were comparable between the two groups, with no selenium-related toxicity, and there were no differences in progression-free and cancer-specific survivals between the two groups. CONCLUSIONS: Intravenous high-dose selenium safely failed to reduce grade 1 or more CIPN, whereas it reduced grade 2 or more motor dysfunction during chemotherapy in patients with PSROC, especially those ≥ 60 years. While the primary endpoint was not met, selenium showed the potential of protective effects against motor neuropathy without safety and survival concerns. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04201561.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 4

Fig. 4 Comparison of A progression-free and B cancer-specific survivals

A

progression-free survival

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

cancer-specific survival

Fig. 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 CONSORT flow diagram (PP, per-protocol; ITT, intention-to-treat)
非 KM Figure
Fig. 2Fig. 2 Change in quality-of-life scores of the EORTC QLQ-C30
非 KM Figure
Fig. 3Fig. 3 Changes in quality-of-life scores of the EORTC-CIPN20: A all patients; B age < 60 years; (C) age ≥ 60 years
非 KM Figure